Introduction {#sec1}
============

Bone defects caused by periodontal disease, trauma, congenital anomalies, infection, and malignancies pose a serious problem in dentistry.[@bib1] Despite various treatment methods and proposed grafting materials, no treatment is available to regenerate bone defects reliably.[@bib2] Autogenous grafts have been used with a high success rate. However, they create a second wound area and postoperative morbidity.[@bib3] Furthermore, surface bone resorption was evident in long-term follow-up studies.[@bib4] Allogenic and alloplastic grafting materials represent a more conservative approach, but they lack osseoinductive properties because of the strict decontamination and sterilization procedures involved in their production.[@bib5] Growth factors have been used as an adjunct to these materials in stimulating new bone formation. This combination is intended to establish a beneficial healing environment and to recreate the former structural integrity of the defective area in a cost-effective and minimally invasive manner.[@bib6] Among these materials, biphasic calcium phosphates constitute a promising alternative by its space-maintaining and regenerative properties in the bone tissue.[@bib5], [@bib6]

When alloplasts are used alone, their osteoinductive characteristics have been shown to be insufficient for bone defect repair, perhaps because they fail to elicit sufficient vital nutrient spread in the bulk graft body.[@bib7] Concurrent use of various growth factors has yielded better outcomes by triggering cellular differentiation and migration within the alloplast body.[@bib8], [@bib9] Bone replacement via alloplast needs to be accompanied by ample vascularization because osteoid deposition and turnover depends on several different cell groups and phases.[@bib10] Vascularization is thus one of the most important prerequisites for bone healing.[@bib11] In previous work, vascular endothelial growth factor (VEGF) has been shown to stimulate local vascular regeneration in bone healing.[@bib12] Moreover, it has been demonstrated that VEGF plays an important role in new bone formation by enhancing chemotaxis of mesenchymal stem cells and by stimulating differentiation and proliferation of osteoblasts via an indirect effect on osteoprogenitor cells.[@bib13] VEGF is produced by various types of cells, including tumor cells, macrophages, platelets, keratinocytes, and renal mesenchymal cells.[@bib14] The functions of VEGF are not limited to the vascular endothelial system.[@bib15] It has been stated that VEGF also plays a role in normal physiological functions such as bone formation, hematopoiesis, and wound healing.[@bib16] Angiogenesis plays an important role in endochondral ossification, the process by which avascular cartilage tissue becomes vascular bone tissue. During bone development, signals required for apoptosis of hypertrophic chondrocytes in epiphyseal growth plaques are provided by new blood vessels. Over the course of this process, VEGF is secreted from hypertrophic chondrocytes; thus, growth of metaphyseal vessels into cartilage tissue and new bone formation occurs.[@bib17] VEGF also has chemotactic effects on osteoblasts. It has been suggested that VEGF has a role in chondrocyte death, chondroclast function, extracellular matrix remodeling, angiogenesis, and regulation of bone formation.[@bib18] As a consequence, VEGF plays an important role in both types of bone healing.

Enhanced healing properties provided by the VEGF may also improve osteogenesis and biodegradation of biphasic calcium phosphates. The aim of this histologic and histomorphometric study was to analyze the effect of VEGF and a biphasic alloplastic graft material (BA), when used alone or in combination on new bone formation in a rat model.

Materials and methods {#sec2}
=====================

Male Wistar rats (*n* = 20) aged 6--8 months and weighing between 350 g and 400 g were used. Approval of the Istanbul University Experimental Animals Ethics Committee (Istanbul, Turkey; No. 2010/160, Date: November 04, 2012) was obtained, and all procedures were conducted in accordance with the Istanbul University ethical guidelines for the treatment and welfare of experimental animals. The surgical procedure was performed by a surgeon (E.B.) licensed to work with experimental animals, and standard surgical techniques were used. General anesthesia was administered using a mixture of 40 mg/kg ketamine-HCl (Alfamine IM, Alfasan International B.V., Woerden, The Netherlands) and 5 mg/kg xylazine HCL (Alfazyne 2% IM, Alfasan International B.V.). Animals were fixed in standard posture, and the distal surface of their right and left femurs was shaved and disinfected with 70% alcohol solution. To reach the distal surface of the femur, 15--20 mm skin and subcutaneous tissue dissection was performed parallel to the long axis using a No. 15 scalpel. Two standard bone defects with a diameter of 3 mm were created using round drills (Gebr. Brasseler GmbH & Co. KG., Lemgo, Germany) in both the right and left femur of each experimental subject under physiological serum irrigation. The 3 × 3 critical-sized defect was based on a previous study.[@bib19]

VEGF 165, which had been isolated from rat blood at the Experimental Medicine Research Institute (EMRI, Istanbul University), was stored in sterile tubes in cold chain and then brought to room temperature before use. Briefly, pcDNA3.1 plasmids were cloned and subjected to an electro-transfer procedure. Then, a toxin-free plasmid was produced, and the final VEGF plasmid was synthesized in a cell culture.

Using a predefined random order, each rat\'s four defects were filled with the following: (1) BA with a granule size of 500--1000 μm and a porosity of 90% (Bone Ceramic; Straumann, Basel, Switzerland; BA group); (2) VEGF alone; (3) VEGF and BA in combination (VEGF + BA group); or (4) nothing, which served as a control ([Figure 1](#fig1){ref-type="fig"}).Figure 1Visual appearance of the randomly allocated groups on the femoral defects: (A) VEGF group, (B) control group; (C) BA group, and (D) BA + VEGF group. BA = biphasic alloplastic graft material; VEGF = vascular endothelial growth factor.

Following the application of the materials, flaps were repositioned with 3.0 silk sutures (Doğsan Medical, Trabzon, Turkey). Mild compression was applied to the surgical site using a gauze tampon. After the surgical procedure, a single dose of tetracycline (Tetra 10 mg/kg intramuscularly; Mustafa Nevzat İlaç Sanayii, İstanbul, Turkey) was administered to the experimental animals via the intraperitoneal route to prevent postoperative infection. All experimental animals were kept in metal cages in an automatized environment at 21 ± 1°C, a relative humidity of 40--60% and 12-hour dark/light cycles until the sacrificing phase. Experimental animals were fed with tap water and standard pellets.

Ten experimental animals were sacrificed at the end of the 7^th^ day and 10 at the end of the 14^th^ day by administering 135 mg/kg sodium pentothal via an intraperitoneal route. Previous studies have found that this timing maximizes the effectiveness of VEGF.[@bib19] Femur bones were separated from muscles with the help of a periosteum elevator and from joints with the help of a scalpel, and they were placed into a 10% formaldehyde solution and sent to a histology laboratory for histomorphometric examination.

Initially, materials were fixed with a 10% buffered formaldehyde solution for 48 hours. After fixation, a solution containing equal amounts of 50% formic acid and 20% sodium citrate was prepared, and the samples were decalcified for 3 days; they were then exposed to routine tissue tracing. Thereafter, 5--7-μm sections were obtained from paraffin blocks, stained with hematoxylin and eosin, and examined under a light microscope.

During histomorphometric analysis, the following areas were measured using the Olympus Analysis Five (Olympus Corporation, Tokyo, Japan) image analysis program: newly formed bone tissue; fibrotic connective tissue, including the spaces resulting from loss of granulation tissue during demineralization; inflammatory cells; and necrotic tissue. The procedure was performed by measuring four separate areas for each of the criteria in four sections obtained from each block and by calculating a mean percentage according to total magnification area.

Data were analyzed using SPSS for Windows 15.0 (SPSS Inc., Chicago, IL, USA). Normality of the data distribution was checked using the Kolmogorov--Smirnov test. Intergroup comparisons of measures that were not normally distributed were performed using Kruskal--Wallis tests, whereas paired comparisons were performed using Mann--Whitney *U* tests. Significance was evaluated at a level of P \< 0.05. A Bonferroni correction was made on measurements derived from the same sample (P \< 0.0125).

Results {#sec3}
=======

Over the course of the healing period, no infection or complication was observed in any of the experimental animals. However, a fracture was detected in the defect area on the 2^nd^ day of the healing period in one animal. This animal was replaced with another animal using the same protocol. Upon retrieval of the bone specimens, it was macroscopically observed that the integrity of the femur bones was preserved, and they showed no infectious reaction.

Histologic observation indicated that the graft particles were in direct contact with the host bone, with new bone growing into the graft-maintained area. This was more clearly seen in the samples from Day 14 than in those from Day 7. Bone deposition was evident at both time points. New bone tissue was integrated with fibrous tissue areas and residual graft particles, indicating graft resorption, in the VEGF and BA+ VEGF groups ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}).Figure 2Histologic samples from animals that have healed for 1 week; hematoxylin and eosin staining: (A) large trabeculae are observed in the control defect; original magnification ×200. (B) Chondral ossification is characterized with fibrosis tissue in the VEGF group; original magnification ×100. (C) New bone deposition around the graft material (arrow) in the BA group; original magnification ×400. (D) Active osteoid deposition on the graft material (arrow) in BA+ VEGF group; original magnification ×100.Figure 3Histologic samples from animals that have healed for 2 weeks; hematoxylin and eosin staining. (A) Thick bone trabeculae surrounded by active connective tissue in the control group; original magnification ×200. (B) New bone trabeculae in the defect region surrounded by numerous blood vessels; original magnification ×200. (C) The graft material is surrounded by new bone deposition (arrow); original magnification ×200. (D) Fibrotic tissues are being replaced by new bone tissue (arrow) surrounded by large blood vessels; original magnification ×200.

Histomorphometric analysis {#sec3.1}
--------------------------

Measured values of inflammation, necrosis, fibrosis and new bone formation areas of the groups on Day 7 and Day 14 are provided in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}.Table 1Inflammation, necrosis, fibrosis and new bone values at the 7^th^ day.Day 7InflammationNecrosisFibrosisNew boneP \< 0.001P \< 0.001P \< 0.001P \< 0.001Control44.3 ± 12.2^a^NS21.1 ± 10.2^e^NS19.4 ± 4, 3^i^NS16.2 ± 3.4^m^n, o, pBA40.7 ± 12.2^b^NS21.1 ± 9.5^f^NS29.6 ± 13.9^j^NS33.1 ± 13.7^n^NSVEGF29.2 ± 15.0^c^a, b, d21.1 ± 9.5^g^e, f, h46.1 ± 6.2^k^i, j, l46.6 ± 5.0^o^NSBA+ VEGF40.6 ± 11.2^d^NS19.4 ± 4.3^h^NS25.9 ± 13.8^l^NS43.4 ± 8.0^p^NS[^1][^2]Table 2Inflammation, necrosis, fibrosis, and new bone values at the 14^th^ day.Day 14InflammationNecrosisFibrosisNew boneP \< 0.001P \< 0.001P \< 0.001P \< 0.001Control4.5 ± 6.0NS1.4 ± 2.9NS45.8 ± 4.1NS46.3 ± 5.0NSBA9.7 ± 2.7NS1.6 ± 2.5NS38.1 ± 11.4NS55.6 ± 14.1NSVEGF7.6 ± 2.5NS0.9 ± 1.9NS46.6 ± 4.5NS53.9 ± 13.3NSBA+ VEGF12.6 ± 7.8NS8.7 ± 2.8NS40.1 ± 7.6NS60.6 ± 16.1NS[^3]

At both time intervals, inflammation and necrosis were significantly lower in the VEGF groups than in other groups (mean ± SD, 19.4 ± 11.16% and 8.86 ± 1.11% inflammation; P \< 0.001; 5.56 ± 1.16% and 1.01 ± 0.86% necrosis, P \< 0.001 on Days 7 and 14, respectively). By contrast, the fibrosis measured in the VEGF group on Day 7 (45.54 ± 9.56%) was significantly higher than in other groups (P \< 0.001). On Day 7, the rate of new bone formation was similar across the BA, VEGF and BA+ VEGF groups (33.10 ± 13.79%, 46.60 ± 5.0%, and 43.40 ± 8.00%, respectively) but was significantly lower in the control group (16.2 ± 3.42%, P \< 0.0001). From Day 7 to Day 14, a statistically significant decrease in inflammation and necrosis was evident in all groups. Fibrosis and new bone formation showed a statistically significant increase on Day 14, except in the VEGF group. On Day 14, differences were no longer discernable between the groups. The highest new bone formation percentage was observed in the BA + VEGF group (60.6 ± 16.15%), but the differences were not significant ([Figure 4](#fig4){ref-type="fig"}).Figure 4The rate of healing variables (inflammation, necrosis, and fibrosis and new bone formation) on Day 7 and Day 14. Pairwise statistical comparisons of the mentioned variables are expressed as letters for easy identification (a, b, c, and d for the inflammation variable; e, f, g, and h for the necrosis variable; i, j, k, and l for the fibrosis variable; and m, n, o, and p for the new bone variable in the control, BA, VEGF, and BA+ VEGF groups, respectively). BA = biphasic alloplastic graft material; VEGF = vascular endothelial growth factor.

Discussion {#sec4}
==========

The regenerative effect of VEGF and BA applied to critical-sized defects in rat femurs was analyzed in this histologic and histomorphometric study. The treatment groups showed meaningful differences in bone formation and related healing variables (inflammation, necrosis, and fibrosis).

The primary goal of the augmentation method is to replace lost bone with living bone tissue so that modern rehabilitation treatments (such as osseointegrated implants or tissue-born prosthesis) can be undertaken. Therefore, any graft material placed into the lost bone volume needs to be vascularized internally to allow cellular infiltration and bone cell migration. Especially in the oral cavity, this process is frequently hampered by poor soft tissue coverage and dehiscence, exposing the graft material to the oral cavity and resulting in complete loss of the grafting material or insufficient bone fill.[@bib20] VEGF may actively contribute to this healing process by enhancing vascularization and soft tissue proliferation on the cellular level.[@bib21] The results of this study also showed that, when compared to a control group, early-term new bone formation can be enhanced by the use of VEGF.

Reis-Filho and colleagues[@bib22] extracted rat second molars and investigated the influence of a similar allograft on VEGF extraction. Maximum VEGF extraction was observed in the 1^st^ week and 2^nd^ week.[@bib22] Wang and colleagues conducted a controlled study in a rabbit model and created 15-mm critical-sized segmental defects in the femur, which were filled with autologous grafts, β-tricalcium phosphate (β-TCP), and vascular bundles. They stated that VEGF was effective in both angiogenesis and ossification, particularly in the first 3 weeks.[@bib23] Kleinheinz et al[@bib24] created a model of mandibular bicortical defects in 56 rabbits and divided them into two groups. In the first group, defects were left empty or were filled with type-I collagen, whereas the defects in the second group were filled with a collagen matrix and recombinant human VEGF. No significant difference was observed between the test and control groups in terms of new bone formation, but significantly higher bone density was observed in the test group.[@bib24] To improve bone gain further, Yonamine and colleagues[@bib25] placed a polylactic--glycolic acid membrane over calvarial defects treated with VEGF microspheres in rats. Radiological and histological evaluations revealed thick mature bone regeneration when VEGF was used in combination with a polylactic--glycolic acid membrane.[@bib25] These results corroborate the outcomes of the present study, and it can be concluded that VEGF may enhance new bone formation at the very early stages of healing.

The time frame over which VEGF is effective was also investigated. It has been demonstrated that secretion of VEGF was limited to the early stages (1--3 weeks) of healing.[@bib26], [@bib27], [@bib28] Accordingly, the present study\'s sample retrieval schedule was employed to investigate the behavior of VEGF when combined with an alloplast (BA).

Such alloplasts (especially calcium phosphates) have been used widely because autologous grafts are difficult to obtain in sufficient quantity and can cause complications in the donor area. Alloplasts are inexpensive and lack the risk of disease transfer.[@bib29], [@bib30] Furthermore, they can be easily combined with various regeneration-inducing growth factors, including VEGF. This may be significant because alloplasts alone are only osteoconductive and frequently heal by stimulating surrounding tissue growth.[@bib21] The main core of alloplasts usually remains intact due to insufficient vascularization and reach of extracellular fluids.[@bib22], [@bib31]

Due to the disadvantages of HA alone, such as its fragile surface characteristics and irregular biodegradation, the use of β-TCP graft material in combination with HA has become widespread.[@bib9], [@bib32] The BA material used in the present study consisted of a combination of HA and β-TCP at ratios of 60% and 40%, respectively. This combination has proven to be safe and optimal for bone defects such as extraction sockets, periodontal and peri-implant regeneration and endodontic surgery.[@bib6], [@bib33] It has been reported that this graft material acts like a skeleton for bone regeneration, does not interact with the physiological bone deposition process, and has high biocompatibility.[@bib2], [@bib34] Due to the amorphous nature and bulk application of these materials, complete bone replacement has not been achieved, especially in the middle region of the material.[@bib7], [@bib34], [@bib35] The present histologic observation suggests that the application of VEGF seems to increase vascular penetration and expedite bone replacement in the BA body. This approach may constitute a basis for the improvement of related alloplasts.

Within the limits of this study, it can be concluded that VEGF makes a significant contribution to recovery and osteogenesis in the early stages of bone defect healing, and its combination with an osteoconductive alloplast (BA) may further enhance new bone formation.
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[^1]: Pairwise statistical comparisons of the mentioned variables are expressed as letters (a, b, c, and d for the inflammation variable; e, f, g, and h for the necrosis variable; i, j, k, and l for the fibrosis variable; and m, n, o, and p for the new bone variable in the control, BA, VEGF, and BA+ VEGF groups, respectively).

[^2]: BA = biphasic alloplastic graft material; NS = not statistically significant; VEGF = vascular endothelial growth factor.

[^3]: BA = biphasic alloplastic graft material; NS = not statistically significant; VEGF = vascular endothelial growth factor.
